Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 2/20 | 0.43 |
| ▸ | FGF1 | P05230 | 3/20 | 0.38 |
| ▸ | FGF2 | P09038 | 2/20 | 0.38 |
| ▸ | SERPINC1 | P01008 | 2/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.32 |
| ▸ | AMDHD2 | Q9Y303 | 1/20 | 0.32 |
| ▸ | HPSE | Q9Y251 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | BDNF | P23560 | 3/20 | 0.30 |
| ▸ | PTN | P21246 | 2/20 | 0.30 |
| ▸ | MDK | P21741 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29535532 | 0.89 | F10 (0.48) | F10FGF1FGF2SERPINC1F2 | |
| SCHEMBL16728933 | 0.86 | MAPK1 (0.40) | F10LGALS3CA2 | |
| SCHEMBL29535299 | 0.86 | MAPK1 (0.40) | F10LGALS3CA2 | |
| SCHEMBL7209912 | 0.85 | F10 (0.42) | F10FGF1FGF2SERPINC1F2 | |
| SCHEMBL21067663 | 0.85 | F10 (0.42) | F10FGF1FGF2SERPINC1F2 | |
| SCHEMBL13286928 | 0.85 | F10 (0.42) | F10FGF1FGF2SERPINC1F2 | |
| SCHEMBL16728926 | 0.85 | F10 (0.42) | F10FGF1FGF2SERPINC1F2 | |
| SCHEMBL20987120 | 0.85 | F10 (0.42) | F10FGF1FGF2SERPINC1F2 | |
| SCHEMBL7209918 | 0.85 | F10 (0.42) | F10FGF1FGF2SERPINC1F2 | |
| SCHEMBL1009127 | 0.85 | F10 (0.42) | F10FGF1FGF2SERPINC1F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122012440-A | Heparin 3-O-sulfate transferase mutant with high enzyme activity and high thermal stability, and encoding gene and application thereof | 山东大学 | 2026-05-12 | — | — | CN | claimed |
| US-20250188506-A1 | ANTICOAGULANT HEPARIN-CHONDROITIN CHIMERIC SACCHARIDE MOLECULE AS WELL AS PREPARATION METHOD AND APPLICATION THEREOF | SHANDONG UNIVERSITY (CN) | 2025-06-12 | — | — | US | claimed |
| CN-116622006-B | Short acting heparin-based anticoagulant compounds and methods | 北卡罗来纳大学查珀尔希尔分校 | 2025-05-30 | — | — | CN | claimed |
| CN-110446511-B | Short acting heparin-based anticoagulant compounds and methods | 北卡罗来纳大学查珀尔希尔分校 | 2024-04-02 | — | — | CN | claimed |
| WO-2024046048-A1 | ANTICOAGULANT HEPARIN-DERIVED OLIGOSACCHARIDE BIPHENYL DIMER, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 山东大学 | 2024-03-07 | — | — | WO | claimed |
| US-20240066048-A1 | SHORT-ACTING HEPARIN-BASED ANTICOAGULANT COMPOUNDS AND METHODS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2024-02-29 | — | — | US | claimed |
| US-11903963-B2 | Short-acting heparin-based anticoagulant compounds and methods | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2024-02-20 | — | — | US | claimed |
| WO-2024032575-A1 | HEPARIN DODECASACCHARIDE CONTAINING DOUBLE ANTITHROMBIN BINDING SEQUENCE, PREPARATION METHOD THEREFOR, AND USE THEREOF | 山东大学 | 2024-02-15 | — | — | WO | claimed |
| CN-116622006-A | Short acting heparin-based anticoagulant compounds and methods | 北卡罗来纳大学查珀尔希尔分校 | 2023-08-22 | — | — | CN | claimed |
| CN-113583151-B | Heparin molecules containing AT binding sequences and continuous 2-O-glucuronic acid residues, and preparation method and application thereof | 山东大学 | 2023-06-20 | — | — | CN | claimed |
| CN-115417937-B | Heparin dodecasaccharide containing double antithrombin binding sequence and preparation method and application thereof | 山东大学 | 2023-06-06 | — | — | CN | claimed |
| WO-2023280235-A1 | HEPARIN MOLECULE CONTAINING AT BINDING SEQUENCE AND CONTINUOUS 2-O-GLUCURONIC ACID RESIDUE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 山东大学 | 2023-01-12 | — | — | WO | claimed |
| US-20220404379-A1 | SEQUENCING METHOD, SYSTEM AND KIT OF LOW MOLECULAR WEIGHT HEPARIN OLIGOSACCHARIDES | SHANDONG UNIVERSITY (CN) | 2022-12-22 | — | — | US | claimed |
| CN-113393904-B | Method and system for detecting low-molecular heparin sugar chain sequence and sequencing kit | 山东大学 | 2022-10-18 | — | — | CN | claimed |
| CN-111154819-B | Non-animal source low molecular weight heparin and preparation method and application thereof | 山东大学 | 2022-08-30 | — | — | CN | claimed |
| US-12636307-B2 | In vitro heparin and heparan sulfate compositions and methods of making and using | TEGA THERAPEUTICS, INC. (US) | 2026-05-26 | — | — | US | disclosed |
| CN-122012440-A | Heparin 3-O-sulfate transferase mutant with high enzyme activity and high thermal stability, and encoding gene and application thereof | 山东大学 | 2026-05-12 | — | — | CN | disclosed |
| EP-4021461-A1 | HEPARIN AND HEPARAN SULFATE FROM MODIFIED MST CELLS AND METHODS OF MAKING AND USING | Tega Therapeutics, Inc. (US) | 2022-07-06 | — | — | EP | disclosed |
| CN-109477829-B | Nuclear magnetic resonance analysis method for glycosaminoglycan, heparin and derivatives thereof | 罗维药物实验室股份有限公司 | 2022-06-21 | — | — | CN | disclosed |
| EP-3969014-A1 | METHOD FOR MODULATING ENDOTHELIAL GLYCOCALYX STRUCTURE | ExThera Medical Corporation (US) | 2022-03-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11903963-B2 | Short-acting heparin-based anticoagulant compounds and methods | HPSE, STS, SULT1A1 | F10 425/4885FGF1 1952/4885FGF2 1449/4885 |
| US-20240066048-A1 | SHORT-ACTING HEPARIN-BASED ANTICOAGULANT COMPOUNDS AND METHODS | HPSE, STS, SULT1A1 | F10 425/4885FGF1 1952/4885FGF2 1449/4885 |
| US-12636307-B2 | In vitro heparin and heparan sulfate compositions and methods of making and using | TPST2, CSGALNACT1, B4GALT1 | F10 3033/4885FGF1 1507/4885FGF2 761/4885 |
| US-20250188506-A1 | ANTICOAGULANT HEPARIN-CHONDROITIN CHIMERIC SACCHARIDE MOLECULE AS WELL AS PREPARATION METHOD AND APPLICATION THEREOF | HPSE, CD44, CSGALNACT1 | F10 46/4885FGF1 1060/4885FGF2 348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.